Immupharma Share Discussion Threads

[master rsi] 14/6/2019 13:31

re - It'a zombie walking

it all sound like you are talking about YOURSELF

STOP advertising yourself you have not paid the fee yet.

[waterloo01] 14/6/2019 13:10

lol trouble is though it failed the trials and no pharma will take it on and start afresh, including phase 1 safety and dosing studies. It'a zombie walking IMO

[deanmatlazin] 14/6/2019 13:06

I think we will get the result in next few weeks. If there is a news about collaborating with other pharma company..this will go up by few hundred percent!

[a_2_b] 14/6/2019 12:09

Maybe news on the horizon

[andrbea] 13/6/2019 16:06

To think we were 120p and confident of Lupus patients (finally) getting benefit from a drug with no excessive side effects (like the in-place commercial drug).
It had been a long wait for those patients, and they are still out there, waiting.
A more precise trial IMO, of the right target patients, could be all that's needed.

[a_2_b] 13/6/2019 13:58

I'd like to see 16p broken that would be nice

[kirk 6] 13/6/2019 12:13

Brilliant uptrend forming before major break to mid 20s

[a_2_b] 13/6/2019 11:54

Not far off anytime before month end although a lot I'm guessing will be waiting for the news

[todpodger] 13/6/2019 11:45

think the giants waking up news imminent imo.

[best1467] 11/6/2019 11:57

Just listened to (The Life Sciences Group )interview independent research they do seem to see some potential in a certain population from the failed trail going forward so maybe some hope left ,let’s see what the extended trail brings.

[master rsi] 11/6/2019 10:52

Another day another rise and so far has settled at 16p +0.60p
after the late spike yesterday

[ny boy] 11/6/2019 10:28

Started accumulating (C4XD), looking interesting after the pull back

[waterloo01] 11/6/2019 06:37

Still hanging out then Nobby and no sold out long ago, but thanks for asking.

[kirk 6] 10/6/2019 21:14

This has now covered any chance of a fall back now and had higher lows. Next leg will be to break into the 20s as we head towards a potential partner sending the price towards the 92p target

[nobbygnome] 10/6/2019 20:42

Another chance for you to ramp it whilst selling in the background eh waterloo....

[waterloo01] 10/6/2019 19:05

Is this dog still barking? It seems to be throwing up a few bones for the nimble traders. Investors? Anyone still hanging in there?

[ny boy] 10/6/2019 18:44

50%+ on last purchase, steady as she goes, same with ITX,FUM! Dyor as usual, some nice buying opportunities around

[master rsi] 10/6/2019 16:44

Finishing at 15.40p +1.20p

spread 15.06 v 15.74p
no "UT" today so there is a middle price finish

[kirk 6] 10/6/2019 16:30

Breakout any day now as predicted. Should see a surge into 20s tomorrow or Wednesday

[master rsi] 10/6/2019 16:19

Going places late on the day, just like last Friday
15p as "AT"

[kirk 6] 10/6/2019 12:34

Nice steady buying looks about to breakout upwards

[kirk 6] 09/6/2019 22:32

Thanks master ! Will this not make the Price to rise

[master rsi] 09/6/2019 22:00

There is still live on the Lupus business
Global Systemic Lupus Erythematous SLE Drug Market Insights Report 2019
: Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono
June 9, 2019

Systemic Lupus Erythematous SLE Drug MarketThe global “Systemic Lupus Erythematous SLE Drug Market” report offers a specified analysis about the different patterns and parameters affecting the development of the global Systemic Lupus Erythematous SLE Drug market. The report also provides an assessment of the effect of the current patterns in the market including the other essential information about the market’s future development. The report comprises the detailed information relating to the growth factors of Systemic Lupus Erythematous SLE Drug market and also provides a forecast for the market growth and its imperative market contenders Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, MedImmune, Sanofi based on the gathered and analyzed data.

Furthermore, The report presents a detailed segmentation Corticosteroids, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Anti-Inflammatories, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Antimalarials, BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS), Immunosuppressive Agents/Immune Modulators, Ant, Market Trend by Application Hospitals, Hospital Pharmacies, Drug Stores, Online Drug Stores of the global market based on technology, product type, application, and various processes and systems. The report provides information on global Systemic Lupus Erythematous SLE Drug market that comprises multiple reputed organizations, manufacturers, and merchants. The report additionally provides an in-detail abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income through providing better products and services, along with after sales practices.

The global Systemic Lupus Erythematous SLE Drug Market report is a comprehensive investigation of the growth drivers industry, present demand in the market, and restrictions. It incorporates the study of new improvements in innovation, complete profiles of major competitors, and unique model study. It offers a market forecast for the upcoming years. The report additionally covers a survey of major and minor features for the established Systemic Lupus Erythematous SLE Drug market players and emerging industries moreover with pointed value-chain analysis.

Read Detailed Index of full Research Study at: hxxps://www.promarketresearch.com/global-systemic-lupus-erythematous-sle-drug-market-2018-43079.html

The global Systemic Lupus Erythematous SLE Drug market report delivers a detailed information regarding different factors driving or constraining business sector development. The report also guides in understanding the principle product segments and its future in different geographical regions. The report includes varying competitive dynamics analysis. It gives a forecast on the estimation of the way of global Systemic Lupus Erythematous SLE Drug market development. It helps in making precise business decisions by providing an overall vision of the market.

There are 15 Chapters to display the Global Systemic Lupus Erythematous SLE Drug market

Chapter 1, Definition, Specifications and Classification of Systemic Lupus Erythematous SLE Drug, Applications of Systemic Lupus Erythematous SLE Drug, Market Segment by Regions;
Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;
Chapter 3, Technical Data and Manufacturing Plants Analysis of Systemic Lupus Erythematous SLE Drug, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;
Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);
Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Systemic Lupus Erythematous SLE Drug Segment Market Analysis (by Type);
Chapter 7 and 8, The Systemic Lupus Erythematous SLE Drug Segment Market Analysis (by Application) Major Manufacturers Analysis of Systemic Lupus Erythematous SLE Drug ;
Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Corticosteroids, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Anti-Inflammatories, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Antimalarials, BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS), Immunosuppressive Agents/Immune Modulators, Ant, Market Trend by Application Hospitals, Hospital Pharmacies, Drug Stores, Online Drug Stores;
Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;
Chapter 11, The Consumers Analysis of Global Systemic Lupus Erythematous SLE Drug ;
Chapter 12, Systemic Lupus Erythematous SLE Drug Research Findings and Conclusion, Appendix, methodology and data source;
Chapter 13, 14 and 15, Systemic Lupus Erythematous SLE Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.
link ....

[zala1] 07/6/2019 15:10

There is an email address you can write to

[ny boy] 07/6/2019 14:10

Looks perky again, still life in the old dog yet, dip buying going on!